Page 2 - ஆராய்ச்சி ஆரம்ப வளர்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆராய்ச்சி ஆரம்ப வளர்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆராய்ச்சி ஆரம்ப வளர்ச்சி Today - Breaking & Trending Today

Editas Medicine Announces First Quarter 2021 Results and

Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end
RUBY trial of EDIT-301 for sickle cell disease active and recruiting
Preclinical ocular data presented at ARVO supports in vivo
gene editing
$723 million
as of March 31, 2021
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021.
“Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage medicines,” said James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine. “We are pleased to announce Dr. Mark Shearman will be joining Editas as Chief Scientific Officer in June 2021. Mark has an outstanding track record of drug discovery and development, an ....

City Of , United Kingdom , United States , Marks Shearman , Mark Shearman , Jamesc Mullen , Research Early Development , European Hematology Association , Merck Co , Merck Kga , Serono Inc , World Medical Innovation Forum , Virtual Congress , Bristol Myers Squibb , University Of Bristol , Genetic Technologies Corporation , Raymond James Human Health Innovation Conference , University Of Nottingham , American Association For Cancer Research , Research Laboratories , Merck Kgaa , Editas Medicine Inc , Association For Research , Strengthening Leadership , Adding Mark , Chief Scientific ,

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City Of , United Kingdom , United States , Marks Shearman , Jamesc Mullen , Genetic Technologies Corporation , Research Early Development , University Of Nottingham , Merck Co , Exchange Commission , Serono Inc , Merck Kga , Research Laboratories , Merck Kgaa , Editas Medicine Inc , Company Executive Vice , University Of Bristol , Executive Vice President , Chief Scientific , Editas Medicine , Chief Executive Officer , Applied Genetic Technologies Corporation , Chief Scientific Officer , Senior Vice President , Early Development , Executive Director ,

Editas Medicine Announces First Quarter 2021 Results and Update

Published: May 05, 2021
Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end
RUBY trial of EDIT-301 for sickle cell disease active and recruiting
Preclinical ocular data presented at ARVO supports in vivo
gene editing
$723 million
as of March 31, 2021
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021.
“Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage medicines,” said James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine. “We are pleased to announce Dr. Mark Shearman will be joining Editas as Chief Scientific Officer in June 2021. Mark has an outstanding track record of dru ....

City Of , United Kingdom , United States , Marks Shearman , Mark Shearman , Cristi Barnett , Jamesc Mullen , Ron Moldaver , Research Early Development , European Hematology Association , Merck Co , Merck Kga , Serono Inc , World Medical Innovation Forum , Virtual Congress , Bristol Myers Squibb , University Of Bristol , Genetic Technologies Corporation , Raymond James Human Health Innovation Conference , University Of Nottingham , Exchange Commission , American Association For Cancer Research , Research Laboratories , Merck Kgaa , Editas Medicine Inc , Association For Research ,

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer
May 05, 2021 06:59 ET
| Source:
Editas Medicine, Inc.
Editas Medicine, Inc.
Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2021, and will lead drug discovery, research, and development for the Company’s pipeline of experimental medicines
.
“We are delighted to have Mark join our team in June. Mark has an outstanding track record of drug discovery and development and leading high performing teams. Specifically, during his career, he has led discovery programs across multiple modalities, including ophthalmology, immunology, and neurology � ....

City Of , United Kingdom , United States , Marks Shearman , Jamesc Mullen , Genetic Technologies Corporation , Research Early Development , University Of Nottingham , Merck Co , Serono Inc , Merck Kga , Research Laboratories , Merck Kgaa , Editas Medicine Inc , Company Executive Vice , University Of Bristol , Executive Vice President , Chief Scientific , Editas Medicine , Chief Executive Officer , Applied Genetic Technologies Corporation , Chief Scientific Officer , Senior Vice President , Early Development , Executive Director , Senior Director ,

Mestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer

Published: Apr 21, 2021
- Backed by leading healthcare investors including SV Health Investors -
Cambridge, UK, 20 April 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced its launch with $11 million seed financing from healthcare investors SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”).
The Company’s mission is to develop new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technologies enable diseased tissues to be analyzed at a single-cell level, and this work has uncovered discrete fibroblast cell sub-populations shared across diseases, acting as “immune sentinels” in perpetuating, and progressing disease. Mestag is building a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and im ....

United States , United Kingdom , Mark Coles , Davida Tuveson , Michael Brenner , Soumya Raychaudhuri , Julia Wilson , Sanofi Aventis , Phouman Ashrafian , Susan Hill , Chris Buckley , Michaelb Brenner , David Tuveson , Research Early Development , Sv Health Investors , Kennedy Institute Of Rheumatology , Lustgarten Foundation , Jjdc Inc , Musculoskeletal Sciences , University Of Oxford , Cancer Center , Nuffield Department Of Orthopaedics , Head Of Group Finance At Horizon Discovery , Infrastructure For Birmingham Health Partners , Jw Communications , Research Crescendo Biologics ,